Hypertension in CKD Market Analysis By Drug Class(Diuretics, RAS Blockade, β - Blockers, Calcium Channel Blockers), By Distribution Channel(Retail Pharmacies, Hospital Pharmacies, Online Pharmacies) & Forecast 2024-2035
- PUBLISHED ON
- 02/03/2023
- NO OF PAGES
- 251
- CATEGORY
- Healthcare & Life Sciences
Rising prevalence of chronic kidney disease (CKD) and diabetic kidney disease (DKD), amongst the age groups is anticipated to drive the market growth over the forecasted period. The growing number of patients undergoing dialysis treatment is anticipated to fuel growth of the global hypertension in CKD market. For example, as per the data issued in the Indian Journal of Public Health (IJPH), in 2018, about 130,000 patients received dialysis treatment in India and the number augmented by nearly 232 patients per million people in India as compared to 2017.
Similarly, as per the Centers for Disease Control and Prevention, (CDC), March 4, 2021, in the U.S., roughly 15% of the U.S. adults or 37 million people are presently suffering from chronic kidney disease. The below graph demonstrates the percentage of U.S. adults in various age groups (18 years and above), suffering from chronic kidney disease:
Moreover, as per the National Institute of Diabetes and Digestive and Kidney Diseases: 2020, high blood glucose can harm the blood vessels in the kidneys, as many people with diabetes also have high blood pressure. This is known as diabetic kidney disease (DKD) in type 2 diabetes. As per the National Center for Biotechnology Information, (NCBI): 2017, the frequency of DKD in most type 2 diabetics, at any point in time, is nearly 30%-50% among the U.S. diabetic adults. This occurrence was ranging among 25% in patients younger than 65 years old to almost 50% with age more than 65 years. Therefore, patients suffering from DKD are at greater chances of suffering from hypertension.
Market companies are indulged in attaining Fast Track Designation for the drugs from the regulatory specialists, which is projected to boost growth of the global hypertension in CKD market over the forecasted period. For example, on March 12, 2020, C.H. Boehringer Sohn AG & Ko. KG and Eli Lilly and Company got the U.S. Food and Drug Administration (FDA) Fast Track designation grant for directing clinical trial of empagliflozin, to check its pharmacokinetics, safety, and efficiency in decreasing the danger of kidney disease progression and cardiovascular demise in adults suffering from chronic kidney disease.
Rising product launches by the market players is anticipated to drive the growth of the global hypertension in CKD market during the prediction period. For example, in 2019, Mankind Pharma introduced anti-hypertensive-drug Zolahart (Azilsartan), which is indicated for 24 hours blood pressure control. It has been found to be efficient in the hypertensive patients with comorbid situations like diabetes and CKD. It fits to the Angiotensin-receptor-blocker class.
The COVID-19 pandemic is anticipated to confine growth of the global hypertension in CKD market over the forecasted period. As per the National Center for Biotechnology Information (NCBI), September 29, 2020, the treatment for chronic kidney diseases might be postponed owing to the pandemic. Furthermore, throughout the COVID-19 pandemic, the handling of kidney disorders patients is suspended or even cancelled owing to the absence of medicines due to uneven supply and transport of drugs.
Furthermore, according to the U.S Food and Drug Administration (FDA), September 18, 2020, the COVID-19 pandemic has disturbed the global drug supply owing to government-mandated or commended temporary shutdowns, safety initiatives to ensure employee health and well-being, insufficient labour force, and limitations on import and export activities, and travel.
Drug Class Insights
On the basis of drug class, the hypertension in CKD market has been categorized into diuretics, RAS blockade, β – blockers, calcium channel blockers, and others. The RAS blockade category is to observe higher adoption of hypertension in CKD during the forecasted period. The major factor boosting the segment is that, it is the first-line choices for decreasing proteinuria and reducing the progression of nephropathy in diabetic patients.
Distribution Channel Insights
On the basis of distribution channel, the hypertension in CKD market has been categorized into retail pharmacies, hospital pharmacies, and online pharmacies. The hospital pharmacies category is to observe higher adoption of hypertension in CKD during the forecasted period. This is mostly owing to the accessibility of experienced healthcare professionals & the safety & efficiency throughout the treatment procedures also increasing hospital administration of patients globally are the major aspects for the growth of the segment.
Region Insights
North America characterized a substantial portion of the complete industry as an outcome of the growing commonness of hypertension in end-stage kidney illness, which is projected to boost the global hypertension in CKD market growth over the estimated time duration. As specified by the Centers for Disease Control and Prevention (CDC) calculations in 2019, hypertension was seen in patients aged 65 or above and undergoing constant kidney infection, and as per a similar source, approximately 125,000 individuals in the U.S. initiated treatment for end-stage kidney infection (ESKD) and closely 726,000 (2 in every 1,000 individuals) in 2018 were on dialysis or had gone over kidney relocation.
Moreover, as per the Centers for Disease Control and Prevention, in 2019, nearly 15% women and 12% men were experiencing from CKD in the U.S. Furthermore, in 26% of the cases, hypertension was the main reason for end-stage renal disease incidences.
Key Companies Insights
The market for hypertension in CKD is moderately competitive. With the rising applications of Hypertension in CKD, new players are considering to enter the market. The companies are also involved in events like joint ventures, acquisitions, partnerships, mergers, and collaborations. These activities aid in growing the effect of the players in the Hypertension in CKD market, ultimately boosting the market growth.
• Novartis International AG
• AstraZeneca Plc
• Eli Lilly and Company
• Teva Pharmaceutical Industries Ltd.
• Sanofi S.A
• KBP Biosciences Holdings Limited
• Ardelyx
• Reata Pharmaceuticals, Inc.
• Kissei Pharmaceutical Co., Ltd.
• C.H. Boehringer Sohn AG & Ko. KG.
• Other players
Some of the Recent Developments:
• In February 2021, AstraZeneca Plc received permission from Drugs Controller General of India (DCGI) for Dapagliflozin tablets for the management of patients suffering from hypertension in chronic kidney disease.
• In June 2020, Ardelyx submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the sanction of tenapanor for the treatment of hyperphosphatemia in the U.S.
Segments
By Drug Class
• Diuretics
• RAS Blockade
• β - Blockers
• Calcium Channel Blockers
• Others
By Distribution Channel
• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies
By Geography
• North America
o U.S.
o Canada
o Mexico
• Europe
o U.K.
o Germany
o France
o Italy
o Spain
o Russia
• Asia-Pacific
o Japan
o China
o India
o Australia
o South Korea
o ASEAN
• Latin America
o Brazil
o Argentina
o Colombia
• MEA
o South Africa
o Saudi Arabia
o UAE
o Egypt
Historic Year: 2016-2022
Forecast: 2024-2035
Quality Assurance Process
- We Market Research’s Quality Assurance program strives to deliver superior value to our clients.
We Market Research senior executive is assigned to each consulting engagement and works closely with the project team to deliver as per the clients expectations.
Market Research Process
We Market Research monitors 3 important attributes during the QA process- Cost, Schedule & Quality. We believe them as a critical benchmark in achieving a project’s success.
To mitigate risks that can impact project success, we deploy the follow project delivery best practices:
- Project kickoff meeting with client
- Conduct frequent client communications
- Form project steering committee
- Assign a senior SR executive as QA Executive
- Conduct internal editorial & quality reviews of project deliverables
- Certify project staff in SR methodologies & standards
- Monitor client satisfaction
- Monitor realized value post-project
Case Study- Automotive Sector
One of the key manufacturers of automotive had plans to invest in electric utility vehicles. The electric cars and associated markets being a of evolving nature, the automotive client approached Straits Research for a detailed insight on the market forecasts. The client specifically asked for competitive analysis, regulatory framework, regional prospects studied under the influence of drivers, challenges, opportunities, and pricing in terms of revenue and sales (million units).
Solution
The overall study was executed in three stages, intending to help the client meet its objective of precisely understanding the entire market before deciding on an investment. At first, secondary research was conducted considering political, economic, social, and technological parameters to get a gist of the various aspects of the market. This stage of the study concluded with the derivation of drivers, opportunities, and challenges. It also laid substantial emphasis on understanding and collecting data not only on a global scale but also on the regional and country levels. Data Extraction through Primary Research
The second stage involved primary research in which several market players and automotive parts suppliers were contacted to study their viewpoint concerning the development of their market and production capacity, clientele, and product line. This stage concluded in a brief understanding of the competitive ecosystem and also glanced through the strategies and pricing of the companies profiled.
Market Estimates and Forecast
In the final stage of the study, market forecasts for the electric utility were derived using multiple market engineering approaches. This data helped the client to get an overview of the market and accelerate the process of investment.
Case Study- ICT Sector
Business process outsourcing, being one of the lucrative markets from both supply- and demand- side, has appealed to various companies. One of the prominent corporations based out of Japan approached us with their requirements regarding the scope of the procurement outsourcing market for around 50 countries. Additionally, the client also sought key players operating in the market and their revenue breakdown in terms of region and application.
Business Solution
An exhaustive market study was conducted based on primary and secondary research that involved factors such as labor costs in various countries, skilled and technical labors, manufacturing scenario, and their respective contributions in the global GDP. A comparative study of the market was conducted from both supply- and demand side, with the supply-side comprising of notable companies, such as GEP, Accenture, and others, that provide these services. On the other hand, large manufacturing companies from them demand-side were considered that opt for these services.
Conclusion
The report aided the client in understanding the market trends, including country-level business scenarios, consumer behavior, and trends in 50 countries. The report also provided financial insights of crucial players and detailed market estimations and forecasts till 2028.
}})
Select a license type that suits your business needs
US $3950
Only Three Thousand Nine Hundred Fifty US dollar
- 1 User access
- 15% Additional Free Customization
- Free Unlimited post-sale support
- 100% Service Guarantee until achievement of ROI
US $4950
Only Four Thousand Nine Hundred Fifty US dollar
- 5 Users access
- 25% Additional Free Customization
- Access Report summaries for Free
- Guaranteed service
- Dedicated Account Manager
- Discount of 20% on next purchase
- Get personalized market brief from Lead Author
- Printing of Report permitted
- Discount of 20% on next purchase
- 100% Service Guarantee until achievement of ROI
US $5950
Only Five Thousand Nine Hundred Fifty US dollar
- Unlimited User Access
- 30% Additional Free Customization
- Exclusive Previews to latest or upcoming reports
- Discount of 30% on next purchase
- 100% Service Guarantee until achievement of ROI